Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity
NCT05822544Phase 1Active, not recruiting
- Sponsor
- OrsoBio
- Start
- Apr 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of TLC-6740 in obesity (5 arms), sponsored by OrsoBio. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at Day 168, Area Under the Curve at Day 168 and 4 more. Started Apr 2023; status: active, not recruiting.
02
Drugs
TLC-6740
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05822544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05822544.